JCI Editorial Board
First-tier potential conflicts of interest

 

AbbVie Pharmaceuticals (T.M. Dawson)

Aeras (M.L. Reitman)

Alliance for Lupus (M.J. Kaplan)

American Gene Technologies International (T.M. Dawson)

Amgen (D.A. Kass)

Ardelyx (M. Donowitz)

Biogen (P.A. Calabresi)

BluebirdBio (J.D. Powell)

Boehringer Ingelheim (D.A. Kass)

CHD Bioscience (W. Nelson)

Commonwealth Foundation (M.Y. Armanios)

Corvus (J.D. Powell)

Digital Harmonic (W. Nelson)

Emulate (M. Donowitz)

Gemstone Biotherapeutics (S. Gerecht)

Genentech (S. Desiderio)

Gilead (T.C. Quinn)

Inhibikase (T.M. Dawson)

Intra-Cellular Therapies (D.A. Kass)

Ionis Pharmaceuticals (C. Sumner)

Janssen (A.M. DeMarzo)

Johnson & Johnson (A.P. Feinberg, C.B. Newgard)

Lilly (C.B. Newgard)

Loxo Oncology (B.H. Park)

MedImmune (P.A. Calabresi)

Merck (M. Donowitz)

miDiagnostics (S.C. Ray)

MycoMed Technologies (K.A. Marr)

Myriad Genetics (A.M. DeMarzo)

Navitor Pharmaceuticals (J.D. Powell)

Neuraly (T.M. Dawson)

NexImmune (J. Schneck)

Novartis (P.A. Calabresi)

Pfizer (D.A. Kass, W. Nelson, C.B. Newgard)

ProQuest Investments (W. Nelson)

Sanofi (J.D. Powell)

SPARC (T.M. Dawson)

Teva Pharmaceutical Industries Ltd. (P.A. Calabresi, W. Nelson)

Thermo Fisher (A.P. Feinberg)

Titan Pharmaceuticals (W.R. Bishai)